BioNTech Gross Profit vs. Total Debt
| 0A3M Stock | USD 112.90 2.16 1.95% |
Gross Profit | First Reported 2010-12-31 | Previous Quarter 3.2 B | Current Value 5.8 B | Quarterly Volatility 4.9 B |
For BioNTech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BioNTech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BioNTech SE utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BioNTech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BioNTech SE over time as well as its relative position and ranking within its peers.
BioNTech |
BioNTech SE Total Debt vs. Gross Profit Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining BioNTech's current stock value. Our valuation model uses many indicators to compare BioNTech value to that of its competitors to determine the firm's financial worth. BioNTech SE is number one stock in gross profit category among its peers. It also is the top company in total debt category among its peers . The ratio of Gross Profit to Total Debt for BioNTech SE is about 571.72 . At this time, BioNTech's Gross Profit is quite stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioNTech's earnings, one of the primary drivers of an investment's value.BioNTech Total Debt vs. Gross Profit
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
BioNTech |
| = | 16.07 B |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
BioNTech |
| = | 28.1 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
BioNTech Total Debt vs Competition
BioNTech SE is the top company in total debt category among its peers. Total debt of Health Care industry is presently estimated at about 237.41 Trillion. BioNTech adds roughly 28.1 Million in total debt claiming only tiny portion of equities under Health Care industry.
BioNTech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in BioNTech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BioNTech will eventually generate negative long term returns. The profitability progress is the general direction of BioNTech's change in net profit over the period of time. It can combine multiple indicators of BioNTech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Net Income Applicable To Common Shares | 11.8 B | 12.4 B | |
| Income Tax Expense | 5.5 B | 5.7 B | |
| Net Interest Income | 349.7 M | 367.2 M | |
| Interest Income | 357.6 M | 375.5 M | |
| Operating Income | 904.2 M | 859 M | |
| Net Income From Continuing Ops | 930.3 M | 883.8 M | |
| Income Before Tax | 1.2 B | 1.1 B | |
| Total Other Income Expense Net | -67.8 M | -64.4 M | |
| Net Income | 930.3 M | 883.8 M | |
| Change To Netincome | 1.4 B | 1.5 B |
BioNTech Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on BioNTech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BioNTech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BioNTech's important profitability drivers and their relationship over time.
Use BioNTech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioNTech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNTech will appreciate offsetting losses from the drop in the long position's value.BioNTech Pair Trading
BioNTech SE Pair Trading Analysis
The ability to find closely correlated positions to BioNTech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioNTech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioNTech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioNTech SE to buy it.
The correlation of BioNTech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioNTech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioNTech SE moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioNTech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your BioNTech position
In addition to having BioNTech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Biotech Thematic Idea Now
Biotech
Companies specialized in biotechnology production and delivery of pharmaceuticals services. The Biotech theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Biotech Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
To fully project BioNTech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of BioNTech SE at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include BioNTech's income statement, its balance sheet, and the statement of cash flows.